Amneal Pharmaceuticals/$AMRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amneal Pharmaceuticals
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Ticker
$AMRX
Sector
Primary listing
Employees
8,700
Headquarters
Website
AMRX Metrics
BasicAdvanced
$4bn
33.47
$0.37
1.32
-
Price and volume
Market cap
$4bn
Beta
1.32
52-week high
$15.42
52-week low
$7.02
Average daily volume
1.6m
Financial strength
Current ratio
2.469
Quick ratio
1.515
Long term debt to equity
6,697.048
Total debt to equity
6,750.837
Interest coverage (TTM)
1.94%
Profitability
EBITDA (TTM)
666.508
Gross margin (TTM)
39.16%
Net profit margin (TTM)
4.01%
Operating margin (TTM)
15.10%
Effective tax rate (TTM)
0.32%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
8.32%
Return on equity (TTM)
-1,864.81%
Valuation
Price to earnings (TTM)
33.468
Price to revenue (TTM)
1.283
Price to book
-87.25
Price to tangible book (TTM)
-3.37
Price to free cash flow (TTM)
20.774
Free cash flow yield (TTM)
4.81%
Free cash flow per share (TTM)
0.598
Growth
Revenue change (TTM)
7.62%
Earnings per share change (TTM)
-981.47%
3-year revenue growth (CAGR)
10.26%
3-year earnings per share growth (CAGR)
-25.37%
What the Analysts think about AMRX
Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.
AMRX Financial Performance
Revenues and expenses
AMRX Earnings Performance
Company profitability
AMRX News
AllArticlesVideos
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
Reuters·1 month ago
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Business Wire·1 month ago
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs